奥马环素：一种新获批的四环素类抗菌药物。
Omadacycline: A Newly Approved Antibacterial from the Class of Tetracyclines.
作者信息
Durães Fernando, Sousa Emília
机构信息
Laboratory of Organic and Pharmaceutical Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal.
CIIMAR, Interdisciplinary Centre of Marine and Environmental Research, University of Porto, Terminal de Cruzeiros do Porto de Leixões, Avenida General Norton de Matos P, 4450-208 Matosinhos, Portugal.
出版信息
Pharmaceuticals (Basel). 2019 Apr 21;12(2):63. doi: 10.3390/ph12020063.
Omadacycline (Nuzyra®) is a new aminomethylcycline, approved by the U. S. Food and Drug Administration in 2018, as a tetracycline antibacterial. It can be used in community-acquired pneumonia and in acute bacterial skin and skin-structure infections. It was developed and is commercialized by Paratek Pharmaceuticals. It is a semisynthetic compound, derived from minocycline, capable of evading widely distributed efflux and target protection antibacterial resistance mechanisms and has demonstrated activity in a broad spectrum of bacteria.
奥马环素（Nuzyra®）是一种新型氨甲基环素，于2018年获得美国食品药品监督管理局批准，属于四环素类抗菌药物。它可用于治疗社区获得性肺炎以及急性细菌性皮肤和皮肤结构感染。该药物由Paratek制药公司研发并实现商业化。它是一种半合成化合物，由米诺环素衍生而来，能够规避广泛存在的外排和靶点保护抗菌耐药机制，并且已在多种细菌中显示出活性。
Zotero 插件